Aflac Cancer Center and Blood Disorders Service
Emory University / Children's Healthcare of Atlanta

Faculty Publications – 2007
(N = 54)

Peer-Reviewed (N = 48)

1. Manco-Johnson MJ, **Abshire TC**, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Funk S, Jacobson L, Valentino LA, Hoots WD, Buchanan GR, DiMichele D, Recht M, Brown D, Leissenger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. *N Engl J Med* 2007;357(6):535-44.

2. Hastings C, Wechsler DS, Stine KC, Graham DK, **Abshire T**. Consensus on a core curriculum in American training programs in pediatric hematology-oncology: a report from the ASPHO Training Committee. *Pediatr Hematol Oncol* 2007;24(7):503-12.

3. Metzger ML, Stewart CE, Freeman BB, Mullen EA, Billups CA, **Alvarado C**, Daw NC, Dome JS: Topotecan is Active Against Wilms' Tumor: Results of a Multi-Institutional Phase II Study. *J Clin Oncol* 2007;25:3130-3136.

4. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, **Archer D**, **Spencer T**, Dillehay D, Kwon B, Chen L, Vella AT, Mittler RS. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. *J Immunol*. 2007;178(7):4194-213.

5. Zerah M, **Briones M**, Hansen I, Dion J, Renfroe B. Resolution of Severe Sinus Vein Thrombosis. *J Pediatr Endocrinol Metab.* 2007;20(6):725-31.

6. De Bortoli M, **Castellino RC**, Skapura DG, Shen JJ, Su JM, Russell HV, Hicks MJ, Man TK, Kim JY. Patched haploinsufficient mouse rhabdomyosarcoma overexpress secreted phosphoprotein 1 and matrix metalloproteinases. *Eur J Cancer* 2007;43(8):1308-1317.

7. **Castellino RC**, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JYH. Overexpressed *TP73* induces apoptosis in medulloblastoma. *BMC Cancer 2007;*7:127.

8. **Castellino RC** and **Durden DL**. Mechanisms of Disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. *Nat Clin Pract Neurol* (Invited review) 2007;3(12):682-693.

9. **Chiang KY**, **Haight A, Horan J**, Olson E, Gartner A, Hartman D, Youssef S, Worthington-White D. Clinical outcomes and graft characteristics in pediatric matched sibling donor transplants using granulocyte colony-stimulating factor-primed bone marrow and steady-state bone marrow. *Pediatr Transplant*. 2007;11(3):279-85.

10. Ide LM, Gangadharan B, **Chiang KY**, **Doering CB**, **Spencer HT**. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. *Blood*. 2007;110(8):2855-63.

11. **Dey N, De PK,** Wang M, Zhang HY, Dobrata EA, Robertson K and **Durden DL.** CSK controls retinoic acid receptor signaling: RAR-cSRC signaling axis is required for neuritogenic differentiation. *Mol. Cell. Biol.* 2007;27:4179-4197.

12. **Doering CB**, **Gangadharan B**, Dukart HZ and **Spencer HT.** Genetically-Modified Hematopoietic Stem Cells Encoding Porcine Factor VIII Induce Procoagulant Activity in Hemophilia A Mice with Pre-existing Factor VIII Immunity. *Mol. Ther.* 2007;15(6):1093-9.

13. Denning G, Jean-Joseph B, Prince C, **Durden DL**, and Vogt PK. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. *Oncogene*, 26(27): 3930-3940, 2007.

14. Li Y, Yan J, **De P**, Chang HC, Yamauchi A, Christopherson KW 2nd, Paranavitana NC, Peng X, Kim C, Munugulavadla V, Kapur R, Chen H, Shou W, Stone JC, Kaplan MH, Dinauer MC, **Durden DL** and Quilliam LA. Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related rap1a and 1b proteins. *J Immunol* 2007;179(12):8322-8331.

15. Giulino, Lisa B. MD; Bussel, James B. MD; Neufeld, Ellis J. MD, PhD**; Pediatric (Dunn)** and Platelet Immunology Committees of the TMH Clinical Trial Network Treatment with Rituximab in Benign and Malignant Hematologic Disorders in Children. Journal of Pediatrics. 150(4):338-44, 344.e1, 2007 Apr.

16. **Gu L**, **Chiang KY**, Zhu N, **Findley HW** and **Zhou M**. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cells. *Exp. Hema.* 2007;35:957-966.

17. Adamkiewicz TV, Szabolcs P, **Haight A,** Baker KS, Staba S, Kedar A, **Chiang KY**, Krishnamurti L, Boyer MW, Kurtzberg J, Wagner JE, Wingard JR, Yeager AM. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. *Pediatr Transplant*. 2007;11(6):641-4.

18. Culler EE, Hillyer CD, **Haight AE**, Castillejo MI, **Josephson CD**. CD36 immunization in a patient undergoing hematopoietic stem cell transplantation. *Pediatr Blood Cancer* 2007;50:660-662.

19. Eggleston B, Patience M, Edwards S, Adamkiewicz T, Buchanan GR, Davies SC, Dickerhoff R, Donfield S, Feig SA, Giller RH, **Haight A, Horan J**, Hsu LL, Kamani N, **Lane P**, Levine JE, Margolis D, Moore TB, Ohene-Frempong K, Redding-Lallinger R, Roberts IA, Rogers ZR, Sanders JE, Scott JP, Sleight B, Thompson AA, Sullivan KM, Walters MC; Multicenter Study of HCT for SCA. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. *Br J Haematol*. 2007;136(4):673-6.

20. Shu, HKG, Sall, WF, Maity A, Tochner ZA, **Janss AJ**, Belasco JB, Rorke-Adams LB, Phillips PC, Sutton LN and Fisher MJ. Childhood intracranial ependymoma: 20 year experience from a single institution. *Cancer* 2007;110:432-441.

21. Harris SB, **Josephson CD**, Kost C Hillyer CD. Hemolysis in a Pediatric Patient Resulting from High Titer Anti-A in a Single Donor Platelet Unit. *Transfusion,* 2007;47:1412-1417.

22. **Josephson CD**, Su LL, Hillyer KL, Hillyer CD. Transfusion in the Patient with Sickle Cell Disease: A Critical Review of the Literature and Transfusion Guidelines. *Transfusion Medicine Review*, 2007:118-133.

23. **Josephson CD** and Hillyer CD. Tissue oversight in hospitals: The role of hospital blood banks and transfusion services. *Transfusion,* 2007;47:194-199.

24. Meyers RL, **Katzenstein HM**, Krailo M, McGahren ED 3rd, Malogolowkin MH. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma. *J Pediatr Surg* 2007;42(12):2050-6.

25. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, **Katzenstein HM**, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. *Clin Cancer Res* 2007;13(6):1783-8.

26. Meyers RL, **Katzenstein HM**, Malogolowkin MH. Predictive value of staging systems in Hepatoblastoma. *J Clin Oncol* 2007;25(6):737; author reply 737-8.

27. **Kean LS**, Adams AB, Strobert E, Hendrix R, Gangappa S, Jones TR, Shirasugi N, Rigby MR, Hamby K, Jiang J, Bello H, Anderson D, Cardona K, Durham MM, Pearson TC, and Larsen CP. Induction of Chimerism in Rhesus Macaques through Stem Cell Transplant and Costimulation Blockade-Based Immunosuppression. *Am J. Transplant* 2007;7(2):320-35.

28. Zahorchak AF, **Kean LS**, Tokita D, Turnquist HR, Abe M, Finke J, Hamby K, Rigby MR, Larsen CP, Thomson AW. Infusion of Stably-Immature Monocyte-Derived Dendritic Cells Plus CTLA4-Ig Modulates Alloimmune Reactivity in Rhesus Macaques. *Transplantation* 2007;84(2):196-206.

29. Linzie K, Trexler A, Pearson TC, Larsen CP, Rigby MR and **Kean LS.** NK cells rapidly reject allogeneic bone marrow in the spleen through a Perforin- and Ly49D-dependent, but NKG2D-independent mechanism. *Am J. Transplant* 2007;7(8):1884-1896.

30. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, **Lane P**, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Ischer R, Mueller Bu, Coates T, Deferasirox in Sickle Cell Investigators. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. *Br J Haematol* 2007;136:501-8.

31. Howell DL, **Lew G**, Comeaux LG, **Meacham LR**. Late effects risk profiles using the long-term follow-up guidelines in identical twin survivors of acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2007;49(3):349-52.

32. Healey,J.F., Parker,E.T., Barrow,R.T., Langley,T.J., Church,W.R., and **Lollar,P**. The humoral response to human factor VIII in hemophilia A mice. *J.Thromb.Haemost*. 2007;5:512-519.

33. Parker ET, **Lollar P**. Contribution of A1 subunit residue Q316 in thrombin-activated fVIII to A2 subunit dissociation. *Biochemistry* 1007;46:9737-9742.

34. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, **Mazewski C,** Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. *Cancer* 2007;110(7):1542-50.

35. Brat DJ. Shehata BM, Castellano-Sanchez AA, Hawkins C, Yost RB, Greco C, **Mazewski C, Janss A**, Ohgaki H, Perry A. Congenital glioblastoma: a clinicopathologic and genetic analysis. *Brain Pathology* 2007;17:276-81.

36. **Meeks SL**, Healey JF, Parker ET, Barrow RT, and **Lollar P**. Anti-human factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. *Blood* 2007;110:4234-4242.

37. Punyko JA, Gurney JG, Baker SK, Hayashi R, Hudson MM, Liu Y, Robison LL, **Mertens AC.** Physical Function and Attainment of Life Goals in Adult Survivors of Childhood and Adolescent Rhabodmyosarcoma: A Report from the Childhood Cancer Survivors Study. *Psycho-Oncology*. 2007;16:26-37.

38. Nathan PC, Ness KK, Greenberg ML, Hudson M, Wolden S, Davidoff A, Laverdiere C, **Mertens A**, Whitton J, Robison LL, Zeltzer L, Gurney JG. Health-related quality of life in adult survivors of childhood Wilms' tumor or neuroblastoma. A report from the Childhood Cancer Survivor Study. *Pediatr Blood Cancer*. 2007;49:704-715.

39. Ness KK, Baker KS, Dengel DR, Youngren N, Sibley S, **Mertens AC**, Gurney JG. Body composition, muscle strength deficits, and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2007;49:975-981.

40. Schultz KAP, Ness KK, Whitton J, Recklitis C, Zebrack B, Robison LL, Zeltzer L, **Mertens AC**. Behavioral and Social Outcomes in Adolescent Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2007;25: 3649-3656.

41. Henderson T, Whitton J, Stovall M, **Mertens A**, Hammond S, Neglia J, Meadows A, Robison L, Diller L. Secondary Sarcomas in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. *J Natl Cancer Inst*. 2007;99:300-8.

42. Florin TA, Fryer GE, Miyoshi T, Weitzman M, **Mertens AC**, Hudson MM, Sklar CA, Emmons K, Hinkle A, Whitton J, Stovall M, Robison LL, Oeffinger KC. Physical Inactivity in Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report from the Childhood Cancer Survivor Study. *Cancer Epidemiol Biomarkers Prev*. 2007;16(7):1356-63.

43. Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR, Lange BJ, **Woods WG**, Arceci RJ and Smith FO. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Cancer Group studies CCG-2891 and -2961. *Blood* 2007;109:2314-21.

44. Hasle H, Alonzo TA, Auvrignon A, **Woods WG,** et al. Momosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. *Blood* 2007;109:464-467.

45. Barnard DR, Alonzo TA, Gerbing R, Lange B, **Woods WG**. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group. *Pediatr Blood Cancer* 2007;49:17-22.

46. Howell Della L, Ward Kevin C, Austin Harland D, Young John L, **Woods WG.** Access to Pediatric Cancer Care by Age, Race, and Diagnosis, and outcomes of Cancer Treatment in Pediatric and Adolescent Patients in the State of Georgia. *J Clin Oncol* 2007;25:4610-4615.

47. Neudorf S, Sanders J, Kobrinsky N, Alonzo TZ, Buston AB, Buckley JD, Howells W, Gold S, Barnard DR, DeSwarte J, Kalousek D, Lange BJ and **Woods WG**. Autologous bone marrow transplantation (ABMT) for children with AML in first remission. *Bone Marrow Transplantation* 2007;40:313-318.

48. Barrette S, Bernstein ML, Robison LL, Samson Y, Brossard J, Weitzman S, **Woods WG**. Incidence of Neuroblastoma After a Screening Program. *J Clin Oncol* 2007;25:4929-4932.

Non-Peer Reviewed Publications (N = 6)

1. **Abshire T**. Hemostasis and thrombosis. Eds. Marc J. Kahn and Stephanie Gregory. American Society of Hematology Self-Assessment Program. Third Edition.; 2007;Chapter 15;361-407.
2. CME supplement-Pipe SW, Valentino LA., Carcao M, **Dunn AL**, Gruppo RA, Hoots WK, Manco-Johnson M, Walsh CE, Young G. Optimizing Outcomes for patients with severe haemophilia A. Haemophilia 2007;13(s4): 1-16.

3. **Mertens AC**. Cause of Mortality in Five-Year Survivors of Childhood Cancer: A Review. *Pediatr Blood Cancer*. 2007;48:723-726.

4. Hawkins MM, **Mertens AC**, Moller TR, Garwicz SA. Suicide among Survivors of Childhood Cancer. [Letter] *J Clin Oncol* 2007;25(6):731-2.

5. **Woods WG**: Letter to the Editor, in response to Y. Kaneko. Neuroblastomas that might benefit from mass screening at 6 months of age in Japan - Response, *Pediatr Blood Cancer* 2007;48:247.

6. Creutzig U, **Woods WG**. Acute Myelogenous Leukemia. In: Bleyer WA, Barr RD, Albritton KH, Phillips M, Siegel S. *Cancer In Adolescents and Young Adults.* Springer, Berlin Heidelberg New York, 2007, pp 99-109.